[1] NCAIDS, NCSTD, China CDC. Update on the AIDS/STD epidemic in China the third quarter of 2018. Chin J AIDS STD, 2018; 24, 1075. (In Chinese
[2] The Chinese People's Political Consultative Conference. China has more than one million people infected with HIV. http://www.rmzxb.com.cn/c/2020-12-30/2750622.shtml. [2021-02-01]. (In Chinese)
[3] The Antiretroviral Therapy (ART) Cohort Collaboration. Prognosis of HIV-1-infected patients up to 5 years after initiation of HAART: collaborative analysis of prospective studies. AIDS, 2007; 21, 1185−97. doi:  10.1097/QAD.0b013e328133f285
[4] Zhang FJ, Dou ZH, Ma Y, et al. Effect of earlier initiation of antiretroviral treatment and increased treatment coverage on HIV-related mortality in China: a national observational cohort study. Lancet Infect Dis, 2011; 11, 516−24. doi:  10.1016/S1473-3099(11)70097-4
[5] He L, Pan XH, Dou ZH, et al. The factors related to CD4+ T-cell recovery and viral suppression in patients who have low CD4+ T cell counts at the initiation of HAART: a retrospective study of the national HIV treatment sub-database of Zhejiang Province, China, 2014. PLoS One, 2016; 11, e0148915. doi:  10.1371/journal.pone.0148915
[6] Vidal F, Leal M, Alcamí J, et al. Current situation of the pharmacogenetics of immune recovery in treated HIV-infected patients. Pharmacogenomics, 2014; 15, 569−72. doi:  10.2217/pgs.14.1
[7] Olsen NJ, Kovacs WJ. Evidence that androgens modulate human thymic T cell output. J Investig Med, 2011; 59, 32−5. doi:  10.2310/JIM.0b013e318200dc98
[8] China CDC. The number of elderly people infected with HIV has increased fivefold in nine years. https://news.china.com/socialgd/10000169/20201202/39029425_all.html. [2021-02-01]. (In Chinese)
[9] Gaardbo JC, Hartling HJ, Gerstoft J, et al. Incomplete immune recovery in HIV infection: mechanisms, relevance for clinical care, and possible solutions. Clin Dev Immunol, 2012; 2012, 670957.
[10] Gazzola L, Tincati C, Bellistré GM, et al. The absence of CD4+ T cell count recovery despite receipt of virologically suppressive highly active antiretroviral therapy: clinical risk, immunological gaps, and therapeutic options. Clin Infect Dis, 2009; 48, 328−37. doi:  10.1086/695852
[11] Zhou C, Zhang W, Lu RR, et al. Benefits of early and immediate initiation of antiretroviral therapy among HIV patients in Chongqing, China. Biomed Environ Sci, 2020; 33, 282−5.